{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:49:07Z","timestamp":1790372947929,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Urinary tract infections (UTI) are often over-diagnosed and over-treated, which can induce and select for resistant pathogens. After observing wide-spread outpatient use of ertapenem, a broad-spectrum antibiotic, a structured antimicrobial stewardship initiative (ASI) to improve appropriate antimicrobial prescribing was undertaken. ASI objectives were to achieve a goal of reducing ertapenem utilization for extended spectrum beta lactamase\n                      <jats:italic>Enterobacteriaceae<\/jats:italic>\n                      (ESBL-EB) UTI by 10% and evaluate the clinical outcomes associated with the ASI.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A pre-to-post cohort study was conducted at a single-center integrated healthcare system between November 1, 2014 and February 26, 2017. An intensive, 90-day, pharmacist-driven, structured ASI was implemented between November 1, 2015 and January 29, 2016. Female patients aged \u226518\u2009years who were treated for an uncomplicated, ESBL-EB urinary tract infection (UTI) were included. Primary outcome was clinical resolution defined as cure, persistence, relapse and recurrence. Secondary outcome measured was monthly ertapenem use expressed as number of days of therapy (DOT)\/1000 adjusted patient days (APD). Segmented regression analysis for interrupted time series was performed to estimate ASI intervention effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 184 patients were included in the study. Ertapenem utilization decreased from 0.0145 DOT\/1000 APD in Nov. 2014 to 0.0078 DOT\/1000 APD Feb. 2017(\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u20090.01). The mean ertapenem DOT declined 19% overall from the pre vs. post intervention periods (32 vs 26,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u20090.01). Frequency of recurrent UTIs between treatments did not significantly differ and no adverse effects were reported in patients treated with aminoglycosides.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A structured ASI for uncomplicated ESBL-EB UTI was associated with a clinically meaningful decrease in ertapenem utilization and once-daily, 5-day aminoglycoside treatment was well-tolerated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-021-06458-0","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T10:04:08Z","timestamp":1629108248000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Retrospective assessment of antimicrobial stewardship initiative in outpatient use of ertapenem for uncomplicated extended spectrum beta lactamase Enterobacteriaceae urinary tract infections"],"prefix":"10.1186","volume":"21","author":[{"given":"Carrie P.","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Delate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia K.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Jau","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,16]]},"reference":[{"key":"6458_CR1","volume":"4","author":"A Zalmanovici Trestioreanu","year":"2015","unstructured":"Zalmanovici Trestioreanu A, Lador A, Sauerbrun-Cutler MT, Leibovici L. Antibiotics for asymptomatic bacteriuria. Cochrane Database Syst Rev. 2015;4:CD009534.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"6458_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/jgs.13836","volume":"64","author":"T Goto","year":"2016","unstructured":"Goto T, Yoshida K, Tsugawa Y, Camargo CA Jr, Hasegawa K. Infectious disease-related emergency department visits of elderly adults in the United States, 2011-2012. J Am Geriatr Soc. 2016;64(1):31\u20136. https:\/\/doi.org\/10.1111\/jgs.13836.","journal-title":"J Am Geriatr Soc"},{"key":"6458_CR3","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.3389\/fmicb.2015.01446","volume":"6","author":"L Cantas","year":"2016","unstructured":"Cantas L, Suer K, Guler E, Imir T. High Emergence of ESBL-Producing E coli cystitis: time to get smarter in Cyprus. Front Microbiol. 2016;6:1446.","journal-title":"Front Microbiol"},{"issue":"1","key":"6458_CR4","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12879-017-2250-y","volume":"17","author":"MM Fernando","year":"2017","unstructured":"Fernando MM, Luke WA, Miththinda JK, Wickramasinghe RD, Sebastiampillai BS, Gunathilake MP, et al. Extended spectrum beta lactamase producing organisms causing urinary tract infections in Sri Lanka and their antibiotic susceptibility pattern -a hospital based cross sectional study. BMC Infect Dis. 2017;17(1):138. https:\/\/doi.org\/10.1186\/s12879-017-2250-y.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"6458_CR5","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1186\/1471-2334-13-523","volume":"13","author":"CL Lim","year":"2013","unstructured":"Lim CL, Lee W, Lee AL, Liew LT, Nah SC, Wan CN, et al. Evaluation of Ertapenem use with impact assessment on extended-spectrum beta-lactamases (ESBL) production and gram-negative resistance in Singapore General Hospital (SGH). BMC Infect Dis. 2013;13(1):523. https:\/\/doi.org\/10.1186\/1471-2334-13-523.","journal-title":"BMC Infect Dis"},{"issue":"5","key":"6458_CR6","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1093\/cid\/ciq257","volume":"52","author":"K Gupta","year":"2011","unstructured":"Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103\u201320. https:\/\/doi.org\/10.1093\/cid\/ciq257.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"6458_CR7","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.cmi.2019.04.013","volume":"25","author":"E Durante-Mangoni","year":"2019","unstructured":"Durante-Mangoni E, Andini R, Zampino R. Management of carbapenem-resistant Enterobacteriaceae infections. Clin Microbiol Infect. 2019;25(8):943\u201350. https:\/\/doi.org\/10.1016\/j.cmi.2019.04.013.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"6458_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4103\/jgid.jgid_72_17","volume":"10","author":"NK Tulara","year":"2018","unstructured":"Tulara NK. Nitrofurantoin and Fosfomycin for extended Spectrum Beta-lactamases producing Escherichia coli and Klebsiella pneumoniae. J Glob Infect Dis. 2018;10(1):19\u201321. https:\/\/doi.org\/10.4103\/jgid.jgid_72_17.","journal-title":"J Glob Infect Dis"},{"issue":"2","key":"6458_CR9","doi-asserted-by":"publisher","first-page":"ofaa034","DOI":"10.1093\/ofid\/ofaa034","volume":"7","author":"CG Derington","year":"2020","unstructured":"Derington CG, Benavides N, Delate T, Fish DN. Multiple-dose oral fosfomycin for treatment of complicated urinary tract infections in the outpatient setting. Open Forum Infect Dis. 2020;7(2):ofaa034.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"6458_CR10","first-page":"e02165","volume":"63","author":"KJ Goodlet","year":"2018","unstructured":"Goodlet KJ, Benhalima FZ, Nailor MD. A systematic review of single-dose aminoglycoside therapy for urinary tract infection: is it time to resurrect an old strategy? Antimicrob Agents Chemother. 2018;63(1):e02165\u201318.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"6458_CR11","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3904\/kjim.2016.31.1.156","volume":"31","author":"SY Cho","year":"2016","unstructured":"Cho SY, Choi SM, Park SH, Lee DG, Choi JH, Yoo JH. Amikacin therapy for urinary tract infections caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli. Korean J Intern Med. 2016;31(1):156\u201361. https:\/\/doi.org\/10.3904\/kjim.2016.31.1.156.","journal-title":"Korean J Intern Med"},{"issue":"2","key":"6458_CR12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/jac\/dkm193","volume":"60","author":"L Vidal","year":"2007","unstructured":"Vidal L, Gafter-Gvili A, Borok S, Fraser A, Leibovici L, Paul M. Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2007;60(2):247\u201357. https:\/\/doi.org\/10.1093\/jac\/dkm193.","journal-title":"J Antimicrob Chemother"},{"issue":"suppl_1","key":"6458_CR13","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1093\/ofid\/ofv133.1004","volume":"2","author":"A Delgado","year":"2015","unstructured":"Delgado A, Lee GC, Gawrys GW, Duhon BM, Koeller JM. Impact of an antimicrobial stewardship initiative on ertapenem use and carbapenem susceptibilities at four community hospitals. Open Forum Infectious Diseases. 2015;2(suppl_1):1451.","journal-title":"Open Forum Infectious Diseases"},{"issue":"2","key":"6458_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/CCM.0000000000003514","volume":"47","author":"AM Morris","year":"2019","unstructured":"Morris AM, Bai A, Burry L, Dresser LD, Ferguson ND, Lapinsky SE, et al. Long-term effects of phased implementation of antimicrobial stewardship in academic ICUs: 2007-2015. Crit Care Med. 2019;47(2):159\u201366. https:\/\/doi.org\/10.1097\/CCM.0000000000003514.","journal-title":"Crit Care Med"},{"issue":"4","key":"6458_CR15","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.pcl.2009.06.002","volume":"56","author":"CD Courtlandt","year":"2009","unstructured":"Courtlandt CD, Noonan L, Field LG. Model for improvement- part1: a framework for healthcare quality. Pediatr Clin North Am. 2009;56(4):757\u201378.","journal-title":"Pediatr Clin North Am"},{"issue":"8","key":"6458_CR16","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1093\/jac\/dkaa131","volume":"75","author":"I Portillo-Calder\u00f3n","year":"2020","unstructured":"Portillo-Calder\u00f3n I, Ortiz-Padilla M, Rodr\u00edguez-Mart\u00ednez JM, de Gregorio-Iaria B, Bl\u00e1zquez J, Rodr\u00edguez-Ba\u00f1o J, et al. Contribution of hypermutation to fosfomycin heteroresistance in Escherichia coli. J Antimicrob Chemother. 2020;75(8):2066\u201375. https:\/\/doi.org\/10.1093\/jac\/dkaa131.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"6458_CR17","doi-asserted-by":"publisher","first-page":"3630","DOI":"10.1093\/jac\/dkz380","volume":"74","author":"T Doesschate","year":"2019","unstructured":"Doesschate T, Abbott IJ, Willems RJL, Top J, Rogers MRC, Bonten MM, et al. In vivo acquisition of fosfomycin resistance in Escherichia coli by fosA transmission from commensal flora. J Antimicrob Chemother. 2019;74(12):3630\u20132. https:\/\/doi.org\/10.1093\/jac\/dkz380.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"6458_CR18","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1093\/jac\/dkaa126","volume":"75","author":"TJ Hatlen","year":"2020","unstructured":"Hatlen TJ, Flor R, Nguyen MH, Lee GH, Miller LG. Oral fosfomycin use for pyelonephritis and complicated urinary tract infections: a 1 year review of outcomes and prescribing habits in a large municipal healthcare system. J Antimicrob Chemother. 2020;75(7):1993\u20137. https:\/\/doi.org\/10.1093\/jac\/dkaa126.","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"6458_CR19","doi-asserted-by":"publisher","first-page":"5744","DOI":"10.1128\/AAC.00402-12","volume":"56","author":"EA Neuner","year":"2012","unstructured":"Neuner EA, Sekeres J, Hall GS, van Duin D. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms. Antimicrob Agents Chemother. 2012;56(11):5744\u20138. https:\/\/doi.org\/10.1128\/AAC.00402-12.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"6458_CR20","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1111\/jgs.13702","volume":"63","author":"The American Geriatrics Society 2015 Beers Criteria Update Expert Panel","year":"2015","unstructured":"The American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatric Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227\u201346.","journal-title":"J Am Geriatr Soc"},{"key":"6458_CR21","unstructured":"CLSI Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. CLSI Guideline M100. Wayne: Clinical and Laboratory Standards Institute; 2020."},{"issue":"10","key":"6458_CR22","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1093\/cid\/ciw118","volume":"62","author":"TF Barlam","year":"2016","unstructured":"Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62(10):e51\u201377. https:\/\/doi.org\/10.1093\/cid\/ciw118.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"6458_CR23","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1093\/cid\/ciy1121","volume":"68","author":"LE Nicolle","year":"2019","unstructured":"Nicolle LE, Gupta K, Bradley SF, Colgan R, DeMuri GP, Drekonja D, et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis. 2019;68(10):e83\u2013e110. https:\/\/doi.org\/10.1093\/cid\/ciy1121.","journal-title":"Clin Infect Dis"},{"key":"6458_CR24","unstructured":"Tamma P, Aitken SL, Bonomoa RA, Mathers AJ, Van Duin D, Clancy CJ. Infectious Diseases Society of America guidance on the treatment of antimicrobial resistant gram-negative infections. Infectious Diseases Society of America 2020; Available at https:\/\/www.idsociety.org\/practice-guideline\/amr-guidance\/."},{"key":"6458_CR25","unstructured":"CDC Assessment of Appropriateness of Antibiotics for Urinary Tract Infection. https:\/\/www.cdc.gov\/antibiotic-use\/healthcare\/pdfs\/UTI-Assessment.docx. Accessed 20 Dec 2019."},{"issue":"8","key":"6458_CR26","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1093\/jac\/dkr207","volume":"66","author":"K Thakkar","year":"2011","unstructured":"Thakkar K, Gilchrist M, Dickinson E, Benn J, Franklin BD, Jacklin A, et al. A quality improvement programme to increase compliance with an anti-infective prescribing policy. J Antimicrob Chemother. 2011;66(8):1916\u201320. https:\/\/doi.org\/10.1093\/jac\/dkr207.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"6458_CR27","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.idc.2014.01.006","volume":"28","author":"OM Ibrahim","year":"2014","unstructured":"Ibrahim OM, Polk RE. Antimicrobial use metrics and benchmarking to improve stewardship outcomes. Methodology, opportunities, and challenges. Infect Dis Clin N Am. 2014;28(2):195\u2013214. https:\/\/doi.org\/10.1016\/j.idc.2014.01.006.","journal-title":"Infect Dis Clin N Am"},{"issue":"23","key":"6458_CR28","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1001\/jama.2014.14042","volume":"312","author":"JS Gerber","year":"2014","unstructured":"Gerber JS, Prasad PA, Fiks AG, Localio AR, Bell LM, Keren R, et al. Durability of benefits of an outpatient antimicrobial stewardship intervention after discontinuation of audit and feedback. JAMA. 2014;312(23):2569\u201370. https:\/\/doi.org\/10.1001\/jama.2014.14042.","journal-title":"JAMA."},{"issue":"1","key":"6458_CR29","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13756-015-0095-y","volume":"4","author":"SB Doernberg","year":"2015","unstructured":"Doernberg SB, Dudas V, Trivedi KK. Implementation of an antimicrobial stewardship program targeting residents with urinary tract infections in three community long-term care facilities: a quasi-experimental study using time-series analysis. Antimicrob Resist Infect Control. 2015;4(1):54. https:\/\/doi.org\/10.1186\/s13756-015-0095-y.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"2","key":"6458_CR30","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1093\/jac\/dkz457","volume":"75","author":"I Zohar","year":"2020","unstructured":"Zohar I, Schwartz O, Yossepowitch O, David SSB, Maor Y. Aminoglycoside versus carbapenem or piperacillin\/tazobactam treatment for bloodstream infections of urinary source caused by gram-negative ESBL-producing Enterobacteriaceae. J Antimicrob Chemother. 2020;75(2):458\u201365. https:\/\/doi.org\/10.1093\/jac\/dkz457.","journal-title":"J Antimicrob Chemother"},{"key":"6458_CR31","volume-title":"New antimicrobial stewardship in ambulatory health care standard","author":"Joint Commission","year":"2020","unstructured":"Joint Commission. New antimicrobial stewardship in ambulatory health care standard (2020). https:\/\/www.jointcommission.org\/standards\/r3-report\/r3-report-issue-23-antimicrobial-stewardship-in-ambulatory-health-care\/. Accessed 15 Apr 2020."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06458-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06458-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06458-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T10:04:22Z","timestamp":1629108262000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06458-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,16]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6458"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06458-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-431269\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,16]]},"assertion":[{"value":"17 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods were carried out in accordance with relevant guidelines and regulations. This study was reviewed and approved by the Kaiser Permanente Southern California (KPSC) Institutional Review Board (IRB) ID 10944. Informed consent was waived by KPSC IRB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Carrie P. Wong, Thomas Delate, Elizabeth Hudson, Julia K. Nguyen, Su-Jau Yang and Mariana Abraham declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"823"}}